{"id":"NCT00644358","sponsor":"Forest Laboratories","briefTitle":"A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)","officialTitle":"A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12-31","primaryCompletion":"2009-05-31","completion":"2009-05-31","firstPosted":"2008-03-26","resultsPosted":"2017-09-25","lastUpdate":"2017-09-25"},"enrollment":616,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"vilazodone","otherNames":["EMD 68843, SB-659746"]}],"arms":[{"label":"Vilazodone","type":"EXPERIMENTAL"}],"summary":"This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD. This study will enroll approximately 600 patients.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"From first dose of study medication and up to 30 days after the last dose of study medication (Up to 13 months)","effectByArm":[{"arm":"Vilazodone","deltaMin":562,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":23},"locations":{"siteCount":38,"countries":["United States"]},"refs":{"pmids":["24127687","23216998","22106941","21869687"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":599},"commonTop":["Diarrhoea","Nausea","Headache","Upper respiratory tract infection","Insomnia"]}}